作者
Wissam Ghusn, Alan De la Rosa, Daniel Sacoto, Lizeth Cifuentes, Alejandro Campos, Fauzi Feris, Maria Daniela Hurtado, Andres Acosta
发表日期
2022/9/1
期刊
JAMA Network Open
卷号
5
期号
9
页码范围
e2231982-e2231982
出版商
American Medical Association
简介
Importance
No retrospective cohort study has assessed the effectiveness of semaglutide at doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg).
Objective
To study weight loss outcomes associated with semaglutide treatment at doses used in randomized clinical trials for patients with overweight or obesity.
Design, Setting, and Participants
This cohort study, conducted at a referral center for weight management, retrospectively collected data on the use of semaglutide for adults with overweight or obesity between January 1, 2021, and March 15, 2022, with a follow-up of up to 6 months. A total of 408 patients with a body mass index (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more. Patients with a history of bariatric procedures, taking other antiobesity medications, and with an active malignant neoplasm were excluded.
Exposures
Weekly 1.7-mg …
学术搜索中的文章
W Ghusn, A De la Rosa, D Sacoto, L Cifuentes… - JAMA Network Open, 2022
